Merck’s Focus On ADCs Expands To Include Protein Degraders With C4

 
• By Joseph Haas
  
Merck makes move into degrader-antibody conjugates via pact with C4
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business